Low Doses of Steroids with Lenalidomide Prolong Survival of Patients with Multiple MyelomaAs per a randomized clinical trial for patients with newly diagnosed multiple myeloma, low doses of the steroid, dexamethasone, along with lenalidomide can help in prolonging survival for multiple myeloma patients.

The trial was conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG) and sponsored by the National Cancer Institute (NCI).

It was revealed during the trial that a combination of dexamethasone (low dosages) and lenalidomide is far effective than lenalidomide and higher doses of dexamethasone.

As per noted study chair Vincent Rajkumar, M.D., Mayo Clinic, Rochester, Minn, these results are expected to have major implications for therapy relevant to multiple myeloma, a cancer typically found in bone marrow.

Rajkumar remarked that the results of this trial are very positive and can be seen as a potential real step ahead in the treatment of multiple myeloma.